191 related articles for article (PubMed ID: 27745933)
1. Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia.
Borghi C; Urso R; Cicero AF
Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):115-120. PubMed ID: 27745933
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?
Koh KK; Sakuma I; Hayashi T; Kim SH; Chung WJ
Expert Opin Pharmacother; 2015 May; 16(7):949-53. PubMed ID: 25747324
[TBL] [Abstract][Full Text] [Related]
3. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
5. Hypercholesterolemia and Hypertension: Two Sides of the Same Coin.
Ivanovic B; Tadic M
Am J Cardiovasc Drugs; 2015 Dec; 15(6):403-14. PubMed ID: 26062915
[TBL] [Abstract][Full Text] [Related]
6. Role of angiotensin II AT1 receptor blockers in the treatment of arterial hypertension.
Contreras F; de la Parte MA; Cabrera J; Ospino N; Israili ZH; Velasco M
Am J Ther; 2003; 10(6):401-8. PubMed ID: 14624277
[TBL] [Abstract][Full Text] [Related]
7. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
Verdecchia P; Gentile G; Angeli F; Reboldi G
Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
[TBL] [Abstract][Full Text] [Related]
8. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin system blocking drugs.
Robles NR; Cerezo I; Hernandez-Gallego R
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
[TBL] [Abstract][Full Text] [Related]
10. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
Gerc V; Buksa M; Loza V; Kulic M
Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
[TBL] [Abstract][Full Text] [Related]
11. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
Borghi C; ; Rossi F;
High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting the renin-angiotensin system: why and in which patients.
Berra K; Miller NH
J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
[TBL] [Abstract][Full Text] [Related]
13. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
14. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. AT1 receptors in the kidney mediate the chronic hypertensive response to angiotensin II.
Crowley SD
J Appl Physiol (1985); 2010 Dec; 109(6):2012-3. PubMed ID: 21188828
[No Abstract] [Full Text] [Related]
15. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
Tempelhof MW
South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
[No Abstract] [Full Text] [Related]
16. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
Chen SS; Seliger SL; Fried LF
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
Oikonomou D; Georgiopoulos G; Katsi V; Kourek C; Tsioufis C; Alexopoulou A; Koutli E; Tousoulis D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):979-985. PubMed ID: 30048367
[TBL] [Abstract][Full Text] [Related]
18. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Angiotensin II type 1 receptor expression in leukocytes of patients with chronic kidney disease.
Chon H; Neumann J; Boer P; Joles JA; Braam B
Eur J Pharmacol; 2011 Sep; 666(1-3):205-10. PubMed ID: 21640098
[TBL] [Abstract][Full Text] [Related]
20. [Hypertension and hypercholesterolemia in the Czech population].
Wohlfahrt P; Krajčoviechová A; Bruthans J; Cífková R
Vnitr Lek; 2016; 62(11):863-867. PubMed ID: 28128571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
